83. Uematsu T, Torimoto K, Tanaka N, Asakawa I, Hori S, Yamaki K, Nakai Y, Miyake M, Anai S, Hasegawa M, Fujimoto K. Factors affecting urinary frequency after low-dose-rate brachytherapy for prostate cancer. Low Urin Tract Symptoms. 14(1):4-9, 2022

84. Nakai Y, Tanaka N, Asakawa I, Miyake M, Anai S, Yamaki K, Hasegawa M, Fujimoto K. Erectile dysfunction and sexual quality of life in patients who underwent low-dose-rate brachytherapy alone for prostate cancer. Andrologia. 54(1):e14288, 2022

85. Owari T, Tanaka N, Nakai Y, Miyake M, Anai S, Torimoto K, Maesaka F, Asakawa I, Yamaki K, Fuji T, Hasegawa M, Fujimoto K. Impact of neoadjuvant androgen deprivation therapy on postimplant prostate D90 and prostate volume after low-dose-rate brachytherapy for localized prostate cancer. Int J Urol. 29(2):143-151, 2022

86. Nakai Y, Tanaka N, Asakawa I, Miyake M, Anai S, Torimoto K, Yamaki K, Fujii T, Hasegawa M, Fujimoto K. Mirabegron Reduces Urinary Frequency and Improves Overactive Bladder Symptoms at 3 Months After ¹²⁵I-brachytherapy for Prostate Cancer: An Open-Labeled, Randomized, Non-Placebo-Controlled Study. Urology. 161:87-92, 2022

87. Tsumura H, Tanaka N, Oguchi T, Owari T, Nakai Y, Asakawa I, Iijima K, Kato H, Hashida I, Tabata KI, Satoh T, Ishiyama H. Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer. Radiat Oncol. 17(1):71, 2022

88. Tsuru S, Tamamoto T, Nakao A, Tanizaki K, Yahagi N. Patient Data Sharing and Reduction of Overtime Work of Nurses by Innovation of Nursing Records Using Structured Clinical Knowledge. Stud Health Technol Inform. 294:525-529, 2022

89. Inoue M, Takahama J, Kunichika H, Shimoda E, Morimoto K, Nikimoto M, Inooka N, Hasegawa M. Efficacy of a combination of transarterial chemoembolization and radiation therapty for patients with hepatochellular carcinoma ineligible for resection or radiofrequency ablation. J Nara Med Assoc. 73 (1,2,3): 1-9, 2022

90. Yamaki K, Wakai N, Matsuda R, Miyasaka T, Inooka N, Inoue K, Miura S, Asakawa I, Hasegawa M. Biological dose evaluation of radiotherapy by equivalent dose in 2Gy fractions (EQD2) in recurrent glioblastoma. J Nara Med Assoc. 73 (1,2,3): 11-20, 2022

91. Miura S, Inoue K, Hontsu S, Tanaka H, Miyauchi M, Yamaki K, Inoue M, Asakawa I, Tamamoto T, Hasegawa M. Carboplatin-Paclitaxel Chemoradiotherapy with 66 Gy for Elderly Patients with Locally Advanced Non-Small-Cell Lung Cancer. J Nara Med Assoc. 73 (1,2,3): 21-28, 2022

92. Tsumura H, Tanaka N, Oguchi T, Owari T, Nakai Y, Asakawa I, Iijima K, Kato H, Hashida I, Tabata KI, Satoh T, Ishiyama H. Comparative effectiveness of low-dose-rate brachytherapy with or without external beam radiotherapy in favorable and unfavorable intermediate-risk prostate cancer. Sci Rep. 12(1):11023, 2022

93. Owari T, Tanaka N, Nakai Y, Miyake M, Anai S, Kishi S, Mori S, Fujiwara-Tani R, Hojo Y, Mori T, Kuwada M, Fujii T, Hasegawa M, Fujimoto K, Kuniyasu H. 5-Aminolevulinic acid overcomes hypoxia-induced radiation resistance by enhancing mitochondrial reactive oxygen species production in prostate cancer cells. Br J Cancer. 127(2):350-363, 2022

94. Nakai Y, Tanaka N, Asakawa I, Morizawa Y, Yamaki K, Hori S, Gotoh D, Miyake M, Torimoto K, Hasegawa M, Fujimoto K. Late genitourinary and gastrointestinal toxicity and radiation-induced second primary cancers in patients treated with low-dose-rate brachytherapy. Brachytherapy. 21(5):626-634, 2022

95. Miyazaki K, Suzuki R, Oguchi M, Taguchi S, Amaki J, Maeda T, Kubota N, Maruyama D, Terui Y, Sekiguchi N, Takizawa J, Tsukamoto H, Murayama T, Ando T, Matsuoka H, Hasegawa M, Wada H, Sakai R, Kameoka Y, Tsukamoto N, Choi I, Masaki Y, Shimada K, Fukuhara N, Utsumi T, Uoshima N, Kagami Y, Asano N, Ejima Y, Katayama N, Yamaguchi M. Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma. Hematol Oncol. 40(4):667-677, 2022

96. Tanaka N, Nakai Y, Asakawa I, Yamaki K, Miyake M, Hori S, Owari T, Fujii T, Fujimoto K. Local dose (biologically effective dose ≥180 Gy2) is an important predictor of biochemical recurrence in patients undergoing low-dose-rate brachytherapy. Int J Urol. 29(12):1560-1568, 2022